Assyro AI

FDA Orange Book · active-ingredient family

Pilocarpine hydrochloride

Pilocarpine hydrochloride is approved as 5 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:QLOSI · NDA 217836

5

Brand (NDA)

10

Generics (ANDA)

6

Listed patents

2

Exclusivity periods

Brand (NDA) products · gel, solution/drops, tablet

ProductApplicantApplicationTEApproved
QLOSIRLDORASIS PHARMSNDA 217836Oct 17, 2023
VUITYRLDABBVIENDA 214028Oct 28, 2021
ISOPTO CARPINERLD×3SANDOZNDA 200890ATJun 22, 2010
SALAGENRLD×2ADVANZ PHARMANDA 020237ABMar 22, 1994
PILOPINE HSALCONNDA 018796Oct 01, 1984

Generic (ANDA) products (10)

ProductApplicantApplicationTEApproved
PILOCARPINE HYDROCHLORIDE×3FDC LTDANDA 217052Oct 02, 2025
PILOCARPINE HYDROCHLORIDEAMNEALANDA 217733Apr 28, 2025
PILOCARPINE HYDROCHLORIDE×3AMNEALANDA 214193ATSep 21, 2020
PILOCARPINE HYDROCHLORIDE×3SOMERSET THERAPS LLCANDA 210384ATNov 25, 2019
PILOCARPINE HYDROCHLORIDE×2AUROBINDO PHARMA USAANDA 212377ABAug 13, 2019
PILOCARPINE HYDROCHLORIDE×3RISINGANDA 204398ATSep 27, 2017
PILOCARPINE HYDROCHLORIDE×2IMPAX LABSANDA 077248ABMar 31, 2006
PILOCARPINE HYDROCHLORIDE×2LANNETT CO INCANDA 077220ABOct 14, 2005
PILOCARPINE HYDROCHLORIDE×2INNOGENIXANDA 076963ABDec 22, 2004
PILOCARPINE HYDROCHLORIDEPADAGIS USANDA 076746Nov 16, 2004

Marketing exclusivity (2)

  • NPNew product exclusivity (3 years)

    Oct 17, 2026

    in 4 mo

  • D-187New indication / change exclusivity (3 years)

    Mar 28, 2026

    3 mo ago

Listed patents (6)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11129812Aug 18, 2037in 11 yr 4 mo
U-3741
10639297Aug 18, 2037in 11 yr 4 mo
ProductU-3741
11974986Aug 18, 2037in 11 yr 4 mo
U-3741
9867810Aug 18, 2037in 11 yr 4 mo
ProductU-3741
10610518Apr 24, 2039in 13 yr
U-3562
11285134Apr 24, 2039in 13 yr
U-3561

Pilocarpine hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.